Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -3.41%33 EV-to-EBITDA is 2.91 as of Aug. 20, 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Standard BioTools ranks better than 96.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Standard BioTools's enterprise value is $-193.96 Mil.
Standard BioTools's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-66.67 Mil. Therefore, Standard BioTools's EV-to-EBITDA for today is 2.91.
The historical rank and industry rank for Standard BioTools's EV-to-EBITDA or its related term are showing as below:
LAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.93 Med: -5.5 Max: 3
Current: 2.91
During the past 13 years, the highest EV-to-EBITDA of Standard BioTools was 3.00. The lowest was -20.93. And the median was -5.50.
LAB's EV-to-EBITDA is ranked better than 96.12% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 15.16
vs LAB: 2.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Standard BioTools (NAS:LAB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Standard BioTools's PE Ratio (TTM) for today is calculated as:
Standard BioTools's share price for today is $0.6487.
Standard BioTools's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Standard BioTools's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Standard BioTools's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Standard BioTools's EV-to-EBITDA falls into.
Standard BioTools's current Enterprise Value is $-193.96 Mil.
Standard BioTools's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (LAB) has a EV-to-EBITDA of 2.91 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Standard BioTools. According to the industry distribution chart, Standard BioTools ranks #20 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 3.9%.
Is Standard BioTools' EV-to-EBITDA too high?
Standard BioTools' current EV-to-EBITDA is 2.91. The Medical Devices & Instruments industry median EV-to-EBITDA is 15.16. Standard BioTools' value of 2.91 is 80.8% below this industry median. Based on the distribution chart, Standard BioTools ranks #20 out of 515 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' EV-to-EBITDA compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #20 out of 515 companies for EV-to-EBITDA. This places Standard BioTools in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.16. Standard BioTools' value of 2.91 is 80.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 15.16, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current EV-to-EBITDA of 2.91 is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Standard BioTools. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current EV-to-EBITDA is 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 8.6% below its estimated fair value. The current EV-to-EBITDA is 2.91 and 80.8% below the Medical Devices & Instruments industry median of 15.16. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Standard BioTools (LAB), the current EV-to-EBITDA is 2.91 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 8.6% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
EV-to-EBITDA: 2.91
GF Value™: $0.71 vs. price of $0.65 (8.6% below fair value)
Industry Position: 80.8% below the Medical Devices & Instruments median (#20 of 515)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
